Evidence map›Paper›PMID 30297701›Full record

ReviewNature reviews. Neurology2018

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Harald Hampel, Sid E O'Bryant, José L Molinuevo, Henrik Zetterberg, Colin L Masters, Simone Lista, Steven J Kiddle, Richard Batrla, Kaj Blennow

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05020626 (Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis), which is not on this map. Cited by 397 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05020626 recruitingnot on this mapstarted 2021, after this paper: background citation

Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis

TypeobservationalSponsorChinese University of Hong KongRan2021 to 2025Enrolled250ConditionsAlzheimer's Disease Diagnosis
3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Integrative Transcriptomics and Mendelian Randomization IdentifyCurrent issues in molecular biology · 2026
    Article
  19. Review
  20. Article

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Harald HampelAXA Research Fund and Sorbonne University Chair, Paris, France. harald.hampel@med.uni-muenchen.de.
Sid E O'BryantUniversity of North Texas Health Science Center, Fort Worth, TX, USA.
José L MolinuevoBarcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Colin L MastersThe Florey Institute, The University of Melbourne, Melbourne, Australia.
Simone ListaAXA Research Fund and Sorbonne University Chair, Paris, France.
Steven J KiddleDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Richard BatrlaRoche Diagnostics International, Rotkreuz, Switzerland.
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. kaj.blennow@neuro.gu.se.

Funding

Medical Research Council MR/L011859/1Medical Research Council MR/P021573/1
6 · The paper itself

Abstract

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic-industry co-development pathway from identification and assay development to validation for clinical use.

Indexed as

Alzheimer DiseaseBiomarkersEarly DiagnosisHumansPrecision MedicineBiomarkers

Identifiers

PMID30297701
PMCPMC6211654

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.